1. Home
  2. NWFL vs CTNM Comparison

NWFL vs CTNM Comparison

Compare NWFL & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Norwood Financial Corp.

NWFL

Norwood Financial Corp.

HOLD

Current Price

$30.76

Market Cap

346.2M

Sector

Finance

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$11.74

Market Cap

489.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NWFL
CTNM
Founded
1870
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
346.2M
489.4M
IPO Year
1996
2024

Fundamental Metrics

Financial Performance
Metric
NWFL
CTNM
Price
$30.76
$11.74
Analyst Decision
Hold
Buy
Analyst Count
1
4
Target Price
$33.00
$19.00
AVG Volume (30 Days)
17.1K
197.5K
Earning Date
04-27-2026
05-13-2026
Dividend Yield
4.39%
N/A
EPS Growth
15150.00
0.46
EPS
0.35
N/A
Revenue
$7,999,000.00
N/A
Revenue This Year
$34.35
N/A
Revenue Next Year
$5.55
N/A
P/E Ratio
$87.57
N/A
Revenue Growth
8.11
N/A
52 Week Low
$23.70
$3.72
52 Week High
$32.36
$16.33

Technical Indicators

Market Signals
Indicator
NWFL
CTNM
Relative Strength Index (RSI) 50.63 42.83
Support Level $28.95 $11.82
Resistance Level $31.00 $13.40
Average True Range (ATR) 0.80 0.93
MACD 0.00 0.01
Stochastic Oscillator 47.61 32.56

Price Performance

Historical Comparison
NWFL
CTNM

About NWFL Norwood Financial Corp.

Norwood Financial Corp is a U.S.-based bank holding company. It offers various personal and business credit services, trust and investment products, and real estate settlement services to consumers, businesses, nonprofit organizations, and municipalities in each of the communities that the bank serves. The bank also manages automated teller machines at its branch location. It serves the Pennsylvanian counties of Wayne, Pike, Monroe, and Lackawanna, as well as Susquehanna County.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: